This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Labs Outpacing the Sector

Barchart computes a technical support level at 65.17 and the stock recently traded at 65.42 which is above its 50 day moving average of 64.61.

Fundamental Factors

Seventeen Wall Street brokerage firms have assigned 21 analysts to monitor the company's numbers. A consensus estimate projects revenue will be up 2.30% this year and another 3.4% next year. Earnings are estimated to increase by 8.40% this year, an additional 6.30% next year and continue to increase annually around 8.54% over the next 5 years.

These numbers resulted in two analysts issuing Strong Buy recommendations to their clients while eight rated it a Buy, 11 a Hold and one a Sell.

The balance sheet gets an A++ rating. The P/E ratio is 13.58 which is slightly less than the market P/E of 14.60. The dividend rate of 3.07% is close to 40% of projected earnings and above the 2.30% dividend rate of the market.

The company markets a wide range of drugs and medical supplies that provide a steady and predictable income stream. The company will split into two divisions later in the year and that new capital structure has not been announced but analysts predict that might enhance stockholder value

Investor Interest: The staff of TheStreet thinks this is an A+ stock and the 2,661 individual investors on Motley Fool feel the same way and voted 96% that they feel the stock will beat the market. Wall Street analysts look for investors to receive a total annual return in the 12% to 14% range over the next five years. Since May total short interest has been steadily declining.

Abbott Labs stock price held up well against its peers over the past year and was up 31%, while Pfizer (PFE - Get Report) was up 30%, Novartis (NVS - Get Report) was up 5% and Merck (MRK - Get Report) was up 36%.

Some quick comparisons of its peers are below.

  • A+ TheStreet staff rating
  • Analysts project revenue to be down 11.40% this year and down another 2.20% next year
  • Earnings estimated to be down 4.30% this year but up 4.50% next year
  • Novartis:
  • A- TheStreet staff rating
  • Analysts project revenue will be down 2.00% this year but up .90% next year
  • Earnings estimated to be down 5.60% this year and up 3.60% next year
  • Merck
  • A+ TheStreet staff rating
  • Analysts project revenue to be down 1.80% this year and down another 2.60% next year
  • Earnings are estimated to be up 1.10% this year but down 2.40% next year
  • Summary: TheStreet staff seems to rate all the major pharmaceutical stocks very highly but Abbott Labs is the only one that analysts predict will have increases in revenue, earnings and total return for both this year and the next.

    If you want a pharma in your portfolio this is a good choice. The steadily increasing and above-average dividend makes this an ideal stock for a conservative IRA that is on a dividend reinvestment program. Growth investors should be looking for stocks that analysts project will have increases of at least 10% in revenue, earnings and total return and this stock falls short from those benchmarks. Conservative investors should like the improving moving averages and turtle channels.

    This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.
    2 of 2

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    Dividend Stock Advisor

    David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Updates with exact steps to take - BUY, HOLD, SELL
    Trifecta Stocks

    Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

    Product Features:
    • Model Portfolio
    • Intra Day Trade alerts
    • Access to Quant Ratings
    Real Money

    More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

    Product Features:
    • Access to Jim Cramer's daily blog
    • Intraday commentary and news
    • Real-time trading forums
    Only $49.95
    14-Days Free
    14-Days Free
    ABT $38.55 -0.77%
    NVS $76.11 -0.95%
    MRK $55.08 -0.40%
    PFE $33.70 2.74%
    AAPL $95.18 1.64%


    Chart of I:DJI
    DOW 17,750.91 -140.25 -0.78%
    S&P 500 2,063.37 -18.06 -0.87%
    NASDAQ 4,763.2240 -54.37 -1.13%

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs